These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. Asbach B; Kliche A; Köstler J; Perdiguero B; Esteban M; Jacobs BL; Montefiori DC; LaBranche CC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Landucci G; Forthal DN; Seaman MS; Hawkins N; Self SG; Sato A; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Francis J; Galmin L; Ding S; Heeney JL; Pantaleo G; Wagner R J Virol; 2016 Apr; 90(8):4133-4149. PubMed ID: 26865719 [TBL] [Abstract][Full Text] [Related]
8. Progresses in DNA-based heterologous prime-boost immunization strategies. Jackson RJ; Boyle DB; Ranasinghe C Methods Mol Biol; 2014; 1143():61-90. PubMed ID: 24715282 [TBL] [Abstract][Full Text] [Related]
9. Type I Interferon Promotes Humoral Immunity in Viral Vector Vaccination. Zhong C; Liu F; Hajnik RJ; Yao L; Chen K; Wang M; Liang Y; Sun J; Soong L; Hou W; Hu H J Virol; 2021 Oct; 95(22):e0092521. PubMed ID: 34495698 [TBL] [Abstract][Full Text] [Related]
10. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Hwang C; Sanda MG Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762 [TBL] [Abstract][Full Text] [Related]
11. Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates. Zhan Y; Deng Y; Huang B; Song Q; Wang W; Yang Y; Dai L; Wang W; Yan J; Gao GF; Tan W Vaccine; 2019 Apr; 37(15):2122-2130. PubMed ID: 30851967 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen. Haq K; Jia Y; Elahi SM; MacLean S; Akache B; Gurnani K; Chattopadhyay A; Nazemi-Moghaddam N; Gilbert R; McCluskie MJ; Weeratna RD Vaccine; 2019 Nov; 37(47):7029-7040. PubMed ID: 31506193 [TBL] [Abstract][Full Text] [Related]
13. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™. Venkatraman N; Anagnostou N; Bliss C; Bowyer G; Wright D; Lövgren-Bengtsson K; Roberts R; Poulton I; Lawrie A; Ewer K; V S Hill A Vaccine; 2017 Oct; 35(45):6208-6217. PubMed ID: 28941620 [TBL] [Abstract][Full Text] [Related]
16. Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. de Cassan SC; Draper SJ Expert Rev Vaccines; 2013 Apr; 12(4):365-78. PubMed ID: 23560918 [TBL] [Abstract][Full Text] [Related]
17. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH; J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588 [TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Kanesa-thasan N; Smucny JJ; Hoke CH; Marks DH; Konishi E; Kurane I; Tang DB; Vaughn DW; Mason PW; Shope RE Vaccine; 2000 Oct; 19(4-5):483-91. PubMed ID: 11027812 [TBL] [Abstract][Full Text] [Related]
19. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200 [TBL] [Abstract][Full Text] [Related]
20. Recombinant poxviruses as mucosal vaccine vectors. Gherardi MM; Esteban M J Gen Virol; 2005 Nov; 86(Pt 11):2925-2936. PubMed ID: 16227213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]